Dermatol. praxi. 2009;3(1):29-30

New findings on biological therapy of plaque psoriasis with etanercept

doc. MUDr. Karel Ettler CSc
Klinika nemocí kožních a pohlavních, LF UK a FN v Hradci Králové

Etanercept is a biological agent inhibiting TNFα and is used, among other things, for the treatment of plaque psoriasis. Its effectiveness

has been confirmed in a number of studies: with routine dosage (50 mg/week by subcutaneous injection), nearly half of the patients

experience a 50% improvement within six months. Etanercept is effective even when readministered and can be used to treat severe

psoriasis in children.

Etanercept is a relatively safe drug; risks of long-term therapy with biologics including possible activation of TB or development of

lymphomas are discussed.

Keywords: etanercept, plaque psoriasis.

Published: April 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ettler K. New findings on biological therapy of plaque psoriasis with etanercept. Dermatol. praxi. 2009;3(1):29-30.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Thaci D. Long-term data in the treatment of psoriasis. Brit. J. Derm. 2008; 159(Suppl. 2): 18-24. Go to original source... Go to PubMed...
    2. Benáková N, Štork J. Novinky v léčbě psoriázy biologiky a standardními systémovými léky. Čes-slov. Derm. 2008; 83(4): 191-202.
    3. Leonardi CI, et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 2003; 349: 2014-2022. Go to original source... Go to PubMed...
    4. Tyring S, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet 2006; 367: 29-35. Go to original source... Go to PubMed...
    5. Papp KA, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Brit. J. Derm. 2005; 152: 1304-1312. Go to original source... Go to PubMed...
    6. van der Kerkhof PCM, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Brit. J. Derm. 2008; 159: 1177-1185. Go to original source... Go to PubMed...
    7. Krueger GG, et al. Patients with psoriasis respond to continous open-label etanercept treatment after initial incomplete responce in a randomized, placebo-controlled trial. J. Am. Acad. Derm. 2006; 3(Suppl. 2) 112-119. Go to original source... Go to PubMed...
    8. Tyring S, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch. Derm. 2007; 143: 719-726. Go to original source... Go to PubMed...
    9. Barrera MV, et al. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur. J. Derm. 2008; 18: 683-687.
    10. Paller AS, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N. Engl. J. Med. 2008; 358: 241-251. Go to original source... Go to PubMed...
    11. Gottlieb AB, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch. Derm. 2003; 139: 1627-1632. Go to original source... Go to PubMed...
    12. Smith CH, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Brit. J. Derm. 2005; 153: 486-497. Go to original source... Go to PubMed...
    13. Bongartz T, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infection and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285. Go to original source... Go to PubMed...
    14. Geborek P, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis but may be associated with an increased risk of lymphomas. Ann. Rheum. Dis. 2005; 64: 699-703. Go to original source... Go to PubMed...
    15. Chong BF, Wong HK. Treatment of psoriasis with etanercept in a patient with a history of primary B-cell lymphoma. Clin. Exp. Derm. 2008, v tisku.
    16. Brimhall AK, et al. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Brit. J. Derm. 2008; 159: 274-285. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.